Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy
Background: The aim of this study was to investigate the effects of surgical castration, particularly delaying the time to entrance of systemic chemotherapy, in castration-resistant prostate cancer (CRPC) patients who were refractory to initial combination androgen deprivation therapy. Materials and...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2015-12-01
|
| Series: | Prostate International |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2287888215300842 |
| _version_ | 1797715022165573632 |
|---|---|
| author | Minyong Kang Sangchul Lee Jong Jin Oh Sung Kyu Hong Sang Eun Lee Seok-Soo Byun |
| author_facet | Minyong Kang Sangchul Lee Jong Jin Oh Sung Kyu Hong Sang Eun Lee Seok-Soo Byun |
| author_sort | Minyong Kang |
| collection | DOAJ |
| description | Background: The aim of this study was to investigate the effects of surgical castration, particularly delaying the time to entrance of systemic chemotherapy, in castration-resistant prostate cancer (CRPC) patients who were refractory to initial combination androgen deprivation therapy.
Materials and methods: We analyzed the clinical data of 14 CRPC patients diagnosed at Seoul National University Bundang Hospital (SNUBH) from November 2008 through May 2015. After exclusion of three patients, we finally analyzed the baseline characteristics of 11 CRPC patients. We also assessed the delaying time of docetaxel administration, which was defined as response duration, after surgical castration.
Results: After bilateral orchiectomy, the treatment response rate was 45.4% and the median duration of response was 9 months (range 4–48 mo). Responders had less aggressive biopsy Gleason scores compared to nonresponders. Notably, responders showed the reducing pattern of serum prostate specific antigen levels, while nonresponders demonstrated increasing tendency after surgical castration. Moreover, responders also presented with a reduction pattern of serum testosterone levels, whereas nonresponders showed an increasing pattern of testosterone levels after bilateral orchiectomy.
Conclusions: In summary, despite the limited number of cases for convincing evidence, our results shed light again on the clinical benefits of surgical castration prior to the systemic chemotherapy in some CRPC patients after initial hormone therapy. |
| first_indexed | 2024-03-12T08:01:44Z |
| format | Article |
| id | doaj.art-31ac5b49c62d48d0918b23dec440842d |
| institution | Directory Open Access Journal |
| issn | 2287-8882 |
| language | English |
| last_indexed | 2024-03-12T08:01:44Z |
| publishDate | 2015-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Prostate International |
| spelling | doaj.art-31ac5b49c62d48d0918b23dec440842d2023-09-02T19:50:45ZengElsevierProstate International2287-88822015-12-013412312610.1016/j.prnil.2015.10.015Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapyMinyong KangSangchul LeeJong Jin OhSung Kyu HongSang Eun LeeSeok-Soo ByunBackground: The aim of this study was to investigate the effects of surgical castration, particularly delaying the time to entrance of systemic chemotherapy, in castration-resistant prostate cancer (CRPC) patients who were refractory to initial combination androgen deprivation therapy. Materials and methods: We analyzed the clinical data of 14 CRPC patients diagnosed at Seoul National University Bundang Hospital (SNUBH) from November 2008 through May 2015. After exclusion of three patients, we finally analyzed the baseline characteristics of 11 CRPC patients. We also assessed the delaying time of docetaxel administration, which was defined as response duration, after surgical castration. Results: After bilateral orchiectomy, the treatment response rate was 45.4% and the median duration of response was 9 months (range 4–48 mo). Responders had less aggressive biopsy Gleason scores compared to nonresponders. Notably, responders showed the reducing pattern of serum prostate specific antigen levels, while nonresponders demonstrated increasing tendency after surgical castration. Moreover, responders also presented with a reduction pattern of serum testosterone levels, whereas nonresponders showed an increasing pattern of testosterone levels after bilateral orchiectomy. Conclusions: In summary, despite the limited number of cases for convincing evidence, our results shed light again on the clinical benefits of surgical castration prior to the systemic chemotherapy in some CRPC patients after initial hormone therapy.http://www.sciencedirect.com/science/article/pii/S2287888215300842Castration-resistant prostate cancerClinical benefitsSurgical castrationTaxane-based chemotherapy |
| spellingShingle | Minyong Kang Sangchul Lee Jong Jin Oh Sung Kyu Hong Sang Eun Lee Seok-Soo Byun Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy Prostate International Castration-resistant prostate cancer Clinical benefits Surgical castration Taxane-based chemotherapy |
| title | Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy |
| title_full | Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy |
| title_fullStr | Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy |
| title_full_unstemmed | Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy |
| title_short | Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy |
| title_sort | surgical castration efficiently delays the time of starting a systemic chemotherapy in castration resistant prostate cancer patients refractory to initial androgen deprivation therapy |
| topic | Castration-resistant prostate cancer Clinical benefits Surgical castration Taxane-based chemotherapy |
| url | http://www.sciencedirect.com/science/article/pii/S2287888215300842 |
| work_keys_str_mv | AT minyongkang surgicalcastrationefficientlydelaysthetimeofstartingasystemicchemotherapyincastrationresistantprostatecancerpatientsrefractorytoinitialandrogendeprivationtherapy AT sangchullee surgicalcastrationefficientlydelaysthetimeofstartingasystemicchemotherapyincastrationresistantprostatecancerpatientsrefractorytoinitialandrogendeprivationtherapy AT jongjinoh surgicalcastrationefficientlydelaysthetimeofstartingasystemicchemotherapyincastrationresistantprostatecancerpatientsrefractorytoinitialandrogendeprivationtherapy AT sungkyuhong surgicalcastrationefficientlydelaysthetimeofstartingasystemicchemotherapyincastrationresistantprostatecancerpatientsrefractorytoinitialandrogendeprivationtherapy AT sangeunlee surgicalcastrationefficientlydelaysthetimeofstartingasystemicchemotherapyincastrationresistantprostatecancerpatientsrefractorytoinitialandrogendeprivationtherapy AT seoksoobyun surgicalcastrationefficientlydelaysthetimeofstartingasystemicchemotherapyincastrationresistantprostatecancerpatientsrefractorytoinitialandrogendeprivationtherapy |